State Update: New York Releases Major Market Conduct Regulations for Pharmacy Benefit Managers

AMCP shared comments with Centers for Medicare & Medicaid Services (CMS) on the proposed 2026 Policy and Technical Changes to the Medicare Advantage (MA) Program. We applaud CMS’ efforts to address obesity and emphasized the importance of managing costs. AMCP urged CMS to issue guidance on managing drugs in this class to effectively treat obesity as a chronic disease. On the Medicare Transaction Facilitator, we advised CMS to avoid adding unnecessary costs and administrative burdens. We support CMS’ focus on increasing access to generics, biosimilars, and other affordable medications. Lastly, we provided insights on proposed changes to Star Ratings, ensuring member perspectives are represented.

On Jan. 20, 2025, newly inaugurated President Trump signed dozens of Executive Orders concerning a number of G.O.P. policy priorities, including but not limited to: immigration and border security, trade and economic policy, the federal workforce, energy and environmental policy, law and order, and social policies. While health care was not a primary focus of these executive actions, President Trump did withdraw the United States from the World Health Organization and revoked several Biden-era actions related to health policy. Executive Orders are directives from the president that manage operations of the federal government, have the effect of law, may be promulgated by government agencies, and may be overturned by judicial review if they lack support by existing law or the Constitution.

The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services, the Department of Labor, and the Department of the Treasure (collectively, the Departments) for the opportunity to provide comments in response to the proposed rule titled “Enhancing Coverage of Preventive Services Under the Affordable Care Act [CMS 9887–P]” published in the Federal Register on October 28, 2024.